Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients

被引：0
|
作者：
Sanjay Kumar Mishra
Pradeep Kumar
Srishti Khullar
Amrita Joshi
Alok Sati
Sonali Vinay Kumar
Deepesh Unni
Atul Kumar
机构：
[1] Army Hospital Research Referral,Department of Ophthalmology
来源：
International Journal of Retina and Vitreous | / 8卷
关键词：
Neovascular age-related macular degeneration; nAMD; Brolucizumab; Aflibercept; VEGF; Indian;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients
    Mishra, Sanjay Kumar
    Kumar, Pradeep
    Khullar, Srishti
    Joshi, Amrita
    Sati, Alok
    Kumar, Sonali Vinay
    Unni, Deepesh
    Kumar, Atul
    INTERNATIONAL JOURNAL OF RETINA AND VITREOUS, 2022, 8 (01)
  • [2] Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial
    Dugel, Pravin U.
    Jaffe, Glenn J.
    Sallstig, Peter
    Warburton, James
    Weichselberger, Andreas
    Wieland, Mark
    Singerman, Lawrence
    OPHTHALMOLOGY, 2017, 124 (09) : 1296 - 1304
  • [3] The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
    Musial-Kopiejka, Magdalena
    Polanowska, Katarzyna
    Dobrowolski, Dariusz
    Krysik, Katarzyna
    Wylegala, Edward
    Grabarek, Beniamin Oskar
    Lyssek-Boron, Anita
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (04)
  • [4] Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid
    Singh, Rishi P.
    Jhaveri, Chirag
    Wykoff, Charles C.
    Gale, Richard P.
    Staurenghi, Giovanni
    Iida, Tomohiro
    Koh, Adrian
    Guruprasad, B.
    Gedif, Kinfemichael
    Singer, Michael
    OPHTHALMOLOGY RETINA, 2022, 6 (05): : 377 - 386
  • [5] Intravitreal brolucizumab in neovascular age-related macular degeneration with limited response to aflibercept
    Hatz, Katja B.
    Cedro, Luca
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [6] Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
    Razavi, Sam
    Kodjikian, Laurent
    Giocanti-Auregan, Audrey
    Dufour, Ingrid
    Souied, Eric
    BMC OPHTHALMOLOGY, 2021, 21 (01)
  • [7] Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
    Sam Razavi
    Laurent Kodjikian
    Audrey Giocanti-Aurégan
    Ingrid Dufour
    Eric Souied
    BMC Ophthalmology, 21
  • [8] Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration
    Hikaru Ota
    Jun Takeuchi
    Yuyako Nakano
    Etsuyo Horiguchi
    Yosuke Taki
    Yasuki Ito
    Hiroko Terasaki
    Koji M. Nishiguchi
    Keiko Kataoka
    Japanese Journal of Ophthalmology, 2022, 66 : 278 - 284
  • [9] Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration
    Ota, Hikaru
    Takeuchi, Jun
    Nakano, Yuyako
    Horiguchi, Etsuyo
    Taki, Yosuke
    Ito, Yasuki
    Terasaki, Hiroko
    Nishiguchi, Koji M.
    Kataoka, Keiko
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2022, 66 (03) : 278 - 284
  • [10] Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration
    Kang, Se Woong
    Choi, Jaehwan
    Sheth, Veeral S.
    Nowosielska, Agnieszka
    Misiuk-Hojlo, Marta
    Papp, Andras
    Brown, David M.
    Lee, Jae-Ho
    Barak, Yoreh
    SCIENTIFIC REPORTS, 2024, 14 (01):
12345